Physician profile
Mark Nils Anders Klein
NPI 1376628529
$3,309.83
in general payments reported to CMS, 2019-2025
29 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $327 · 2021: $701 · 2022: $500 · 2023: $539 · 2024: $487 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268 · Education: $58.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,267.82 |
| Education | $58.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $281.55 | 2019-2023 | Korsuva, Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $274.34 | 2021-2025 | |
| W. L. Gore & Associates, INC. | $272.44 | 2021-2023 | Gore Acuseal Vascular Graft |
| Akebia Therapeutics INC | $253.60 | 2019-2024 | Auryxia, Vafseo |
| Aurinia Pharma U.S., INC. | $234.55 | 2022-2025 | Lupkynis |
| Amgen INC. | $217.43 | 2019-2024 | Parsabiv, Tavneos, Aranesp |
| Otsuka America Pharmaceutical, INC. | $206.34 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $203.52 | 2019-2024 | Velphoro |
| Astrazeneca Pharmaceuticals LP | $174.21 | 2020-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $142.82 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $137.66 | 2020-2023 | Benlysta, Jesduvroq |
| Mallinckrodt Hospital Products INC. | $132.65 | 2020-2024 | Acthar, Terlivaz |
| Novartis Pharmaceuticals Corporation | $130.99 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $124.53 | 2019-2025 | Rayaldee |
| Baxter Healthcare | $89.30 | 2024 | Renal - Pd |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $72.40 | 2022-2024 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $62.32 | 2020-2023 | Ultomiris |
| Vanda Pharmaceuticals INC. | $55.15 | 2022 | |
| Bard Peripheral Vascular, INC. | $44.47 | 2019-2021 | |
| Lilly USA, LLC | $37.63 | 2024 | Jardiance |
| Mallinckrodt Enterprises LLC | $30.45 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.48 | 2025 | |
| Ardelyx, INC. | $18.72 | 2024 | Ibsrela |
| Becton, Dickinson and Company | $17.94 | 2025 | Covera |
| Nxstage Medical, INC. | $17.72 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.59 | 2025 | Tryvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.05 | 2024 | Jardiance |
| Genentech USA, INC. | $13.33 | 2019 | |
| Travere Therapeutics, INC. | $12.65 | 2024-2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.